Breakthrough pain and rapid-onset opioids in patients with cancer pain: a narrative review

키워드

참고문헌 (53)

1. van den Beuken-van Everdingen MH, "Update on prevalence of pain in patients with cancer : systematic review and meta-analysis", J Pain Symptom Manage, 51, pp.1070~1090 (2016)
2. van den Beuken-van Everdingen MH, "Treatment of pain in cancer: towards personalised medicine", Cancers(Basel), 10, pp.502~ (2018)
3. Müller-Schwefe G, "Pain in the cancer patient : different pain characteristics CHANGE pharmacological treatment requirements", Curr Med Res Opin, 30, pp.1895~1908 (2014)
4. Caraceni A, "Breakthrough pain characteristics and syndromes in patients with cancer pain : an international survey", Palliat Med, 18, pp.177~183 (2004)
5. Greco MT, "Quality of cancer pain management : an update of a systematic review of undertreatment of patients with cancer", J Clin Oncol, 32, pp.4149~4154 (2014)
6. Davies AN, "The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland", Eur J Pain, 13, pp.331~338 (2009)
7. Fortner BV, "Description and predictors of direct and indirect costs of pain reported by cancer patients", J Pain Symptom Manage, 25, pp.9~18 (2003)
8. Portenoy RK, "Breakthrough pain: definition, prevalence and characteristics", Pain, 41, pp.273~281 (1990)
9. Coluzzi PH, "Cancer pain management : newer perspectives on opioids and episodic pain", Am J Hosp Palliat Care, 15, pp.13~22 (1998)
10. Davies AN, "Breakthrough cancer pain(BTcP)management : a review of international and national guidelines", BMJ Support Palliat Care, 8, pp.241~249 (2018)
11. "Adult cancer pain: version 1" (2023)[URL]
12. Mercadante S, "Episodic(breakthrough)pain : consensus conference of an expert working group of the European Association for Palliative Care", Cancer, 94, pp.832~839 (2002)
13. Løhre ET, "From"breakthrough"to"episodic"cancer pain? : a European Association for Palliative Care Research Network Expert Delphi Survey toward a common terminology and classification of transient cancer pain exacerbations", J Pain Symptom Manage, 51, pp.1013~1019 (2016)
14. Davies A, "Breakthrough cancer pain : an observational study of 1000 European oncology patients", J Pain Symptom Manage, 46, pp.619~628 (2013)
15. Mercadante S, "Italian Oncological Pain Survey(IOPS) : a multicentre Italian study of breakthrough pain performed in different settings", Clin J Pain, 31, pp.214~221 (2015)
16. Saini A, "Circadian variation of breakthrough pain in cancer patients", Eur J Pain, 17, pp.264~270 (2013)
17. Boceta J, "Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study", Clin Transl Oncol, 18, pp.1088~1097 (2016)
18. Smith H, "A comprehensive review of rapid-onset opioids for breakthrough pain", CNS Drugs, 26, pp.509~535 (2012)
19. Davies A, "Multi-centre European study of breakthrough cancer pain : pain characteristics and patient perceptions of current and potential management strategies", Eur J Pain, 15, pp.756~763 (2011)
20. Deandrea S, "Prevalence of breakthrough cancer pain : a systematic review and a pooled analysis of published literature", J Pain Symptom Manage, 47, pp.57~76 (2014)
21. Svendsen KB, "Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms", Eur J Pain, 9, pp.195~206 (2005)
22. Soden K, "How do nurses assess and manage breakthrough pain in specialist palliative care inpatient units? : a multicentre study", Palliat Med, 24, pp.294~298 (2010)
23. Hjermstad MJ, "Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review", J Pain Symptom Manage, 41, pp.1073~1093 (2011)
24. Brunelli C, "Comparison of numerical and verbal rating scales to measure pain exacerbations in patients with chronic cancer pain", Health Qual Life Outcomes, 8, pp.42~ (2010)
25. Mercadante S, "Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients", Curr Med Res Opin, 29, pp.93~97 (2013)
26. Daeninck P, "Canadian recommendations for the management of breakthrough cancer pain", Curr Oncol, 23, pp.96~108 (2016)
27. Webber K, "Accuracy of a diagnostic algorithm to diagnose breakthrough cancer pain as compared with clinical assessment", J Pain Symptom Manage, 50, pp.495~500 (2015)
28. Hagen NA, "The Alberta Breakthrough Pain Assessment Tool for cancer patients : a validation study using a Delphi process and patient think-aloud interviews", J Pain Symptom Manage, 35, pp.136~152 (2008)
29. Webber K, "Development and validation of the breakthrough pain assessment tool(BAT)in cancer patients", J Pain Symptom Manage, 48, pp.619~631 (2014)
30. Ahmad I, "Pain management in metastatic bone disease : a literature review", Cureus, 10, pp.e3286~ (2018)
31. Mazzotta M, "Patients’ satisfaction with breakthrough cancer pain therapy : a secondary analysis of IOPS-MS Study", Cancer Manag Res, 14, pp.1237~1245 (2022)
32. Mercadante S, "Pharmacotherapy for breakthrough cancer pain", Drugs, 72, pp.181~190 (2012)
33. Zeppetella G, "Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management", Eur J Cancer Care(Engl), 18, pp.331~337 (2009)
34. Mercadante S, "Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine", J Pain Symptom Manage, 32, pp.175~179 (2006)
35. Stanley TH, "The fentanyl story", J Pain, 15, pp.1215~1226 (2014)
36. Lötsch J, "Pharmacokinetic-pharmacodynamic modeling of opioids", J Pain Symptom Manage, 29(5 Suppl), pp.S90~S103 (2005)
37. Streisand JB, "Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate", Anesthesiology, 88, pp.305~309 (1998)
38. Darwish M, "Clinical pharmacology of fentanyl buccal tablet for the treatment of breakthrough pain", Expert Rev Clin Pharmacol, 1, pp.39~47 (2008)
39. Portenoy RK, "A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer", Clin J Pain, 22, pp.805~811 (2006)
40. Chwieduk CM, "Fentanyl sublingual : in breakthrough pain in opioid-tolerant adults with cancer", Drugs, 70, pp.2281~2288 (2010)
41. Davies A, "The influence of low salivary flow rates on the absorption of a sublingual fentanyl citrate formulation for breakthrough cancer pain", J Pain Symptom Manage, 51, pp.538~545 (2016)
42. Foster D, "Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery", Ann Pharmacother, 42, pp.1380~1387 (2008)
43. Panagiotou I, "Intranasal fentanyl : from pharmacokinetics and bioavailability to current treatment applications", Expert Rev Anticancer Ther, 10, pp.1009~1021 (2010)
44. Lötsch J, "Pharmacokinetics of non-intravenous formulations of fentanyl", Clin Pharmacokinet, 52, pp.23~36 (2013)
45. Zeppetella G, "A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes", J Pain Symptom Manage, 47, pp.772~785 (2014)
46. Mercadante S, "Factors influencing the use of opioids for breakthrough cancer pain : a secondary analysis of the IOPS-MS study", Eur J Pain, 23, pp.719~726 (2019)
47. Cuomo A, "Careful breakthrough cancer pain treatment through rapid-onset transmucosal fentanyl improves the quality of life in cancer patients : results from the BEST Multicenter Study", J Clin Med, 9, pp.1003~ (2020)
48. Mercadante S, "Dosing fentanyl buccal tablet for breakthrough cancer pain : dose titration versus proportional doses", Curr Med Res Opin, 28, pp.963~968 (2012)
49. Yen TY, "Proportional dose of rapid-onset opioid in breakthrough cancer pain management: an open-label, multicenter study", Medicine(Baltimore), 97, pp.e11593~ (2018)
50. Mercadante S, "The prevalence and characteristics of breakthrough cancer pain in patients receiving low doses of opioids for background pain", Cancers(Basel), 13, pp.1058~ (2021)
51. Passik SD, "Weighing in on the off-label use of Actiq for noncancer-related pain : a recipe for success or a recipe for disaster", Pain Med, 8, pp.130~133 (2007)
52. Mercadante S, "The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids", Support Care Cancer, 25, pp.645~649 (2017)
53. Preux C, "Prevalence of opioid use disorder among patients with cancer-related pain : a systematic review", J Clin Med, 11, pp.1594~ (2022)

관련 논문AI추천